Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, was featured in this week’s edition of the UK weekly broadsheet, The Sunday Times (16th of January, 2011).
As part of a pullout focusing on recent developments in life sciences and biotechnology, the article, entitled ‘Better diagnosis, less cost’, describes how OGT’s recent innovations in the fields of biomarker discovery and chromosome analysis will help push healthcare costs down, while improving the accuracy of early disease diagnosis.
In a proof-of-principle case study, protein markers that correctly indicated the presence of prostate cancer with over 90% accuracy were identified using OGT’s biomarker discovery technology. As well as protein based screens, OGT employs its expertise in the design of DNA microarrays to improve genetic tests for developmental delay and other unexplained genetic abnormalities.
This is achieved using OGT’s CytoSure™ arrays and software, which deliver a five-fold improvement in accuracy over traditional karyotyping techniques when used to detect genetic aberrations.